| P |
|
P2Y12 Receptor – Mediated Thromboxane A2 Generation in Human Platelets Occurs in A GIRK – Dependent Manner
|
| Shankar H, Lakhani P, Prabhakar J, Kunapuli SP |
| |
|
P2Y12 Receptor Stimulation Prolongs Thrombin-Induced Calcium Responses and Procoagulant Activity Via Novel Signaling Pathways; Variable Effect of Clopidogrel Treatment
|
| Van der Meijden PEJ, Feijge MAH, Van Raak EPM, Heemskerk JWM |
| |
|
PAI-1 and Atherothrombosis
|
| Vaughan DE |
| |
|
PAR1- and S1P Pathway-Dependent Protection of Endothelial Barrier Integrity by Activated Protein C and Thrombin
|
| Feistritzer C, Lenta R, Riewald M |
| |
|
PAR3 Expression and Functions Studied with Blocking, Cleavage Site-Specific Antibodies
|
| Petrova Y, Kameneva O, Zhukova A, Scudder L, Gnatenko D, Bahou W, Skok M |
| |
|
Paracrine Loop between VEGF-C/Flt-4 and PDGF-BB/PDGFR-Beta Systems Contributes Therapeutic Angiogenesis Using FGF-2 Gene Transfer in Ischemic Hind Limbs
|
| Onimaru M, Yonemitsu Y, Tanii M, Fujii T, Kono R, Nakano T, Nakagawa K, Sueishi K |
| |
|
Paradoxical Example of Warfarin Exerting Anti-Thrombotic Effect without Significantly Altering Template Bleeding Times in Rabbits
|
| Peterson JT, McClanahan T, Hicks G, Baxi SM, Peng Y-M, Chi L, Leadley RJ |
| |
|
Parallel Changes in Procoagulant Activity and Proangiogenic Capacity of Breast Cancer and Leukaemia Cells Exposed to All Trans Retinoic Acid (ATRA)
|
| Marchetti M, Balducci D, Russo L, Vignoli A, Barbui T, Falanga A |
| |
|
Parnaparin Prevents Platelet-PMN Leukocyte Interaction: New Clues to the Antithrombotic Properties of Low Molecular Weight Heparin
|
| Maugeri N, de Gaetano G, Barbanti M, Donati MB, Cerletti C |
| |
|
Parnaparin Prevents the Upregulation of Platelet-Leukocyte Interaction in Whole Blood
|
| Maugeri N, de Gaetano G, Barbanti M, Donati MB, Cerletti C |
| |
|
PARs (Protease Activated Receptors) Activation by Thrombin and Factor Xa Protects Hippocampal Neurons against Glutamate-induced Apoptosis
|
| Storozhevykh T, Gorbacheva L, Kiseleva E, Pinelis V, Strukova S |
| |
|
Partial Purification of ADAMTS-13
|
| Powazniak Y, Kempfer A, Amaral M, Farías C, Vera E, Lazzari M |
| |
|
Pathogenesis of Increased VWF Levels and the Association with the Risk of Ischemic Stroke: Proteolysis, Inflammation or Genetic Variation?
|
| Bongers TN, Gomez GEB, van Goor MPJ, Bhagwanbali V, van Vliet HHDM, de Maat MPM, Dippel DWJ, Leebeek FWG |
| |
|
Pathophysiology of the Antiphospholipid Syndrome
|
| de Groot PG, Derksen RHWM |
| |
|
Patient Outcome during Oral Anticoagulant Therapy Using an Electronic Decision Support System
|
| Franow H, Brandslund I, Steffensen FH |
| |
|
Patient Preference and Willingness-To-Pay Among Different Oral Anticoagulant Treatment Options
|
| Svensson PJ, Andersson S, Westlund A |
| |
|
Patient Privacy and Data Security in Web-Based Databases
|
| Riske B, Bidlingmaier C |
| |
|
Patients with Mucocutaneous Bleeding and Hereditary Disorders of Primary Haemostasis Have Higher Plasma proCPU Levels But a Similar Distribution of the 325 Thr/Ile Polymorphism Compared to Age and Sex Matched Healthy Controls
|
| Matus V, Willemse J, Quiroga T, Leurs J, Sim Y, Goycoolea M, Aranda E, Panes O, Pereira J, Hendriks D, Mezzano D |
| |
|
Paxillin and Hic-5 Function as Csk Binding Proteins and Regulate SFK Activity in Collagen-stimulated Murine Platelets
|
| Rathore V, Newman PJ, Newman DK |
| |
|
Pediatric Reference Intervals for Five Coagulation Assays
|
| Michele MF, Ronda C, William R, George MR |
| |
|
Pediatric Thrombosis
|
| Serbic O, Micic D, Veljkovic D, Rakicevic Lj, Djordjevic V, Vlahovic G, Zamurovic D, Rasovic N, Kuzmanovic M, Bunjevacki G, Slavkovic B, Zdravkovic S |
| |
|
Pegylated Interferon and Ribavirin Anti-hepatitis C Therapy in Patients with Hemophilia Is as Effective and Safe as in Non-hemophilic Patients
|
| ME Mancuso, E Santagostino, MG Rumi, F De Filippi, S Linari, A Coppola, A Rocino, A Iorio, A Dragani, G Barillari, G Tagariello, R Nicolin, M Colombo, PM Mannucci |
| |
|
Pentoxifylline Protects Rats from Endotoxin-Induced Disseminated Intravasvular Coagulation by Inhibiting the Elevations of TNFa and Tissue Factor
|
| He SL, He R, Xiao SH, Li JC |
| |
|
Pentraxin 3 in Patients with Pulmonary Embolism
|
| Sohne M, Gibson NS, Gerdes VEA, Mantovani A, Peri G, Buller HR |
| |
|
Performance Evaluation of APC Resistance/FV Leiden Assay Applications on Routine Coagulation Analyzers
|
| Gringel E, Hafner G, Lichte A, Engelhardt W |
| |
|
Perinatal or Fetal Thrombosis in Babies Allowing Detection of the Anti-phospholipid Syndrome in Mothers
|
| Boffa MC, Aurousseau MH, Lachassinne E, Rai R, Avcin T, Fain O, Douard P, Farge D, Sangle S, Piette JC, Regan L, Uzan M, Hughes GRV |
| |
|
Perioperative Prophylaxis Against Thromboembolism in Patients Undergoing Craniotomy for Brain Tumor: Analysis of Efficacy of Early Low Molecular Weight Heparin
|
| Van den Berg E, Bahr W, van Eck ATCJ, Schmutzler-Baas A, Hamacher J, Ulrich F |
| |
|
Peripheral Artery Disease: Use of Clopidogrel
|
|
| |
|
Permeability of Fibrin Clots: Influence of Fibrinogen Concentration
|
| Savushkin AV |
| |
|
Persistent Hypercoagulability and Risk of Cancer in Older Men
|
| MacCallum PK, Miller GJ, Cooper JA, Howarth DJ |
| |
|
Persistently Reduced D-dimer Levels by the Oral Direct Thrombin Inhibitor Ximelagatran Indicate Reduced Risk of New Ischemic Events after Myocardial Infarction
|
| Christersson C, Oldgren J, Bylock A, Wallentin L, Siegbahn A |
| |
|
Perturbation of pKa Values of Catalytic Residues in the NATURAL Thrombin: Mutant with Deletion of Lys9 in The A-Chain
|
| De Cristofaro R, Carotti A, Akhavan S, Palla R, Peyvandi F, Altomare C, Mannucci PM |
| |
|
Pharmacodynamics of TGN 255, A Novel Intravenous Low Molecular Weight Direct Thrombin Inhibitor, in Healthy Subjects
|
| Combe S, Chander C, Kennedy A |
| |
|
Pharmacogenetic Effect of Factor VII -323 Del/Ins Polymorphism on Diurnal Variation of Factor VII Coagulant Activity and INR in Steady Anticoagulated Patients with Atrial Fibrillation
|
| Roldán V, Corral J, Marín F, del Rey ML, Vicente V, González-Conejero R |
| |
|
Pharmacogenetics of Warfarin–Cytochrome Cyp2c9 and Vitamin K Epoxide Reductase Gene Polymorphisms in Russian Population
|
| Vavilova T, Ulitina A, Sirotkina O |
| |
|
Pharmacokinetic Study of the Co-administration of a Von Willebrand Factor (VWF) Product Containing Low FVIII Level (WILFACTIN) with a Factor VIII Product
|
| Borel-Derlon A, Rothschild C, Torchet MF, Stieltjes N, Borg JY, Fressinaud E, Polack B, Scherrmann JM, Debray M, Caron C, Bridey F, Tellier Z |
| |
|
Pharmacokinetics and Pharmacodynamics of TGN 167, a Novel Oral Direct Thrombin Inhibitor in Healthy Volunteers
|
| Combe S, Allen G, Kennedy A |
| |
|
Pharmacokinetics and Pharmacodynamics of TGN 255, A Novel Intravenous Direct Thrombin Inhibitor in Healthy Volunteers. Comparison with Unfractionated Heparin
|
| Combe S, Chander C, Allen G, Kennedy A |
| |
|
Pharmacokinetics and Pharmacodynamics of the Direct Thrombin Inhibitor Dabigatran in Elderly Healthy Subjects
|
| Stangier J, Stähle H, Rathgen K, Seitz Ch |
| |
|
Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran in a Dose Finding Trial in Atrial Fibrillation
|
| Stangier J, Nehmiz G, Reilly P, Ezekowitz M, Petersen K-E, Simmers T, Wallentin L |
| |
|
Pharmacokinetics of C1 Esterase Inhibitor, Human (Pasteurized) in Subjects with Hereditary Angioedema
|
| Martinez Saguer I, Stoll H, Knaub S, Klingebiel T, Kreuz W |
| |
|
Pharmacokinetics of TGN 255, a Novel Intravenous Low Molecular Weight Direct Thrombin Inhibitor, in Healthy Volunteers
|
| Combe S, Allen G, Kennedy A |
| |
|
Pharmacokinetics, Efficacy and Safety of Solvent/Detergent (S/D) Treated Plasma in Patients with Rare Inherited Coagulation Disorders (RICDs)
|
| Santagostino E, Morfini M, Mancuso ME, Schiavoni M, Tagliaferri A, Barillari G, Mannucci PM |
| |
|
Pharmacological Characterization, Antithrombotic and Bleeding Effects of DU-176b, a Novel, Potent and Orally Active Direct Inhibitor of Factor Xa: A Wider Safety Margin of Antithrombotic and Bleeding Effects Compared to Heparin, LMWH and Warfarin
|
| Furugohri T, Isobe K, Honda Y, Matsumoto C, Sugiyama N, Morishima Y, Shibano T |
| |
|
Pharmacological Properties of YM-254890, a Specific Gaq/11 Inhibitor, on Thrombosis and Neointima Formation in Mice
|
| Kawasaki T, Uemura T, Taniguchi M, Moritani Y, Shigenaga T, Takamatsu H, Hayashi K, Saito T, Takasaki J, Uchida W, Miyata K |
| |
|
Pharmacovigilance Evaluation with ReFacto®– 6 years Post-Licensure Experience With ReFacto®– Recombinant Factor VIII – in Germany and Austria
|
| Pollmann H, Externest D |
| |
|
Phase 1 Pharmacokinetic, Pharmacodynamic, and Safety Evaluation of a Novel Rapidly Reversible Intravenous Platelet P2Y12 ADP Receptor Antagonist, INS50589
|
| Johnson FL, Boyer J, Crean CS, Durham T, Krishnamoorthy R, Kellerman DJ |
| |
|
Phenotype Correction of Hemophilia a Mice with Adeno-associated Virus (AAV) Vectors Carrying the B domain Deleted Canine Factor VIII Gene
|
| Mimuro J, Ishiwata A, Kashiwakura Y, Takano K, Ohmori T, Madoiwa S, Sugo T, Mizukami H, Naka H, Yoshioka A, Ozawa K, Sakata Y |
| |
|
Phenotype Correction of Hemophilia A Mice with Adeno-associated Virus (AAV) Vectors Carrying the B domain Deleted Canine Factor VIII Gene
|
| Mimuro J, Ishiwata A, Kashiwakura Y, Takano K, Ohmori T, Madoiwa S, Sugo T, Mizukami H, Naka H, Yoshioka A, Ozawa K, Sakata Y |
| |
|
Phosphatidylserine Exposure During Platelet Stimulation Is Caused by Activation of Scramblase and Inactivation of Aminophospholipid Translocase in a Distinct Platelet Fraction
|
| Wolfs J, Comfurius P, Rasmussen J, Lindhout T, Zwaal R, Bevers E |
| |
|
Phosphatidylserine-Positive Erythrocytes Modulate Tissue Factor Activity in vivo and in vitro in Sickle Cell Disease
|
| Setty BNY, Key NS, Stuart MJ |
| |
|
Phospholipid Correction of Prolonged Kaolin Clotting Times. Validating the Diagnosis of a Lupus Anticoagulant
|
| Williams V, Griffiths ABM, Patel P, Carbone S |
| |
|
Phospholipids (PL) Induce a Conformational Change Required for Protein Z-Dependent Protease Inhibitor (ZPI) Inhibition of Factor Xa But Not Factor IXa
|
| Cabral KMS, Tonnu L, Heeb MJ |
| |
|
Phosphorylation of the Extracellular Domain of the F11R/JAM-1 and Its Role in Platelet Aggregation
|
| Sobocka MB, Ehrlich YH, Babinska A, Sobocki T, Tullo L, Ghaznawi F, Banerjee P, Marmur J, Kornecki E |
| |
|
Physician Practices for Providing Venous Thromboembolism Prophylaxis to Hospitalized Acutely Ill Medical Patients: Findings from the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE)
|
| Tapson VF, Bergmann JF, Chong BH, Merli GJ, Nakamura M, Pavanello R, Pini M, Piovella F, FitzGerald G, Anderson, Jr FA |
| |
|
Physiopathology and Diagnosis of Heparin-Induced Thrombocytopenia
|
| Gruel Y |
| |
|
Pilot Dose Finding and Pharmacokinetic Study of Bivalirudin in Infants with Thrombosis
|
| Young G, Tarantino MD, Wohrley J, Weber L, Belvedere M, Nugent DJ |
| |
|
Pilot Study of a New Hemostasis Screening Test (HST) Developed by Modification of the Activated Partial Thromboplastin Time (aPTT)
|
| Stoffman JM, Houston DS |
| |
|
Pilot Study: Aspirin Resistance and/or Platelet Hypersensitivity in Cerebrovascular Disease
|
| Münster M, Philippides M, Connor M, Jacobson BF |
| |
|
PIOPED Ventilation-perfusion Scan Reporting: The Inter-observer Variation
|
| Hogg K, Dawson D, Prescott M, Mackway-Jones K |
| |
|
PKCalpha Coordinates Syk and Src Signalling in Human Platelets
|
| Pula G, Crosby D, Baker J, Poole AW |
| |
|
Plasma Clot: Kinetics of Permeability and Hydraulic Resistance during Fibrinolysis
|
| Savushkin AV |
| |
|
Plasma Concentrations of Soluble Fibrin, D-dimer, Myeloperoxidase and Pregnancy Associated Plasma Protein A before and after Treatment with PCI or Thrombolysis for Acute Myocardial Infarction
|
| Hetland Ø, Brugger Andersen T, Poenitz V, Nilsen DWT |
| |
|
Plasma Ecto-NTPDase Prevents Platelet P2X1 and P2Y12 Receptor Desensitization During Storage
|
| Cauwenberghs S, Feijge MAH, Hoylaerts M, Hageman G, van Pampus ECM, Akkerman JWN, Curvers J, Heemskerk JWM |
| |
|
Plasma Fibrinogen and Viscosity and Risk of Cognitive Decline in Elderly Patients with Vascular Risk Factors or Disease
|
| Rumley A, Stott DJ, Lowe GDO, Murray H, Westendorp RGJ |
| |
|
Plasma Homocysteine and Coronary Artery Disease (CAD) in Asian Indians: An Unlikely Risk Factor
|
| Mukherjee M, Joshi S, Shetty KR |
| |
|
Plasma Levels of Gas6 and its Soluble Receptors In Severe Sepsis: Diagnostic and Prognostic Implications
|
| Burnier L, Fumeaux T, Plaisance S, Collen D, Carmeliet P, Bounameaux H, Pugin J, Angelillo-Scherrer A |
| |
|
Plasma Levels of PAI-1 and Risk of Death from Dengue: No Association with the 4G/5G Promoter Polymorphism
|
| Mairuhu A, Setiati T, Koraka P, Hack C, Leyte A, Faradz S, ten Cate H, Brandjes D, Osterhaus A, Reitsma P, van Gorp E |
| |
|
Plasma Levels of Tissue Factor and Soluble E-Selectin in Sickle Cell Disease: Relationship to Genotype and to Inflammation
|
| Mohan JS, Lip GYH, Bareford D, Blann AD |
| |
|
Plasma Levels of Tissue Factor and von Willebrand Factor Predict Long Term Clinical Outcome after Percutaneous Coronary Revascularization
|
| Susen S, Sautiere K, Zawadzki C, Mouquet F, Dallongeville J, Goudemand J, Lablanche JM, Jude B, Van Belle E |
| |
|
Plasma Lipids and Lipoproteins in Healthy Subjects are Closely Related to INR
|
| Nielsen MB, Bülow R, Aardestrup IV, Schmidt EB, Christensen JH |
| |
|
Plasma Prion Protein (PrPC) in Patients with Vascular Diseases
|
| Starke R, Mackie I, Drummond O, MacGregor I, Harrison P, Machin S |
| |
|
Plasma proCPU (TAFI) Concentrations and Clot Lysis Time Are Not Different in a Chilean Population of Young Healthy Individuals Subgrouped According to the Naturally Occurring 325 Thr/Ile Polymorphism
|
| Willemse J, Matus V, Quiroga T, Sim Y, Goycoolea M, Aranda E, Panes O, Leurs J, Pereira J, Mezzano D, Hendriks D |
| |
|
Plasma Proteomics in Human Endotoxemia: A Novel Approach Using MALDI-TOF Profiling and iTRAQ Labeling Reveals Oxidation Of Plasma Proteins and Other Significant Changes
|
| Kasthuri RS, Martinez MB, Jilma B, Key NS, Nelsestuen GL |
| |
|
Plasma TFPI Levels in Patients Undergoing Regular Hemodialysis and Treated with Erythropoietin
|
| Kubisz P, Ivanková J, Peterková M, Funiaková S, Hollý P, Stas[scaron]ko J |
| |
|
Plasma Warfarin and The Ratio of S- and R-Enantiomers in Patients Correlated to the International Normalized Ratio
|
| Osman M, Arbring K, Lindahl T |
| |
|
Plasmatic and Urinary Tissue Factor (TF) And Its Inhibitor (TFPI) Do Not Reflect the Activity of Human Chronic Glomerulonephritis
|
| Naumnik B, Borawski J, Chyczewski L, Kovalchuk O, My[sacute]liwiec M |
| |
|
Plasminogen Activator Inhibitor-1 -675 4G/5G and a -844 G Polymorphisms and Outcome of Patients with Sepsis
|
| Apergis G, Bellia M, Kofinas G, Andrioti E |
| |
|
Plasminogen Activator Inhibitor-1 Plasma Levels Increase after Myocardial Ischemia/Reperfusion Injury in Mice
|
| Loubele S, Frederix K, van Oerle R, Strzelecka A, Spronk HMH, Hamulyák K, van der Voort D, ten Cate H |
| |
|
Plasminogen Activator Releasing Activity in Coffee
|
| Sumi H, Yamanaka T, Ohsugi T |
| |
|
Plasminogen Inhibits Monocyte Apoptosis
|
| Mitchell J, Baik N, Castellino F, Miles L |
| |
|
Platelet aIIbb3 Integrin Constrained in the Extended Conformer Represents an Highly Activated Form
|
| Kamata T, Handa M, Ikeda Y, Aiso S |
| |
|
Platelet Activation and Interaction of rFVIIa (NovoSeven®) with COAT Platelets Following Cardiopulmonary Bypass
|
| Kjalke M, Johansson P, Runge M, Hughes P, Steinbrüchel D, Rojkjaer R |
| |
|
Platelet Activation by Limited Proteolysis of PAR-1, and -4 and its Role in Activation of Coagulation: a Mathematical Model
|
| Druzhinin AV, Khanin MA |
| |
|
Platelet Activation by Oxidized Low-Density Lipoprotein Is Mediated by CD36 and Scavenger Receptor-A
|
| Korporaal SJA, van Eck M, Bezemer M, van Berkel ThJC, Lenting PJ, Akkerman JWN |
| |
|
Platelet Activation during Stress in Hyperhomocysteinemic Rats
|
| Pavlova N, Cherkasova K, Rudko I, Romanova E, Kubatiev A |
| |
|
Platelet Activation in Whole Blood, Red Cell Concentrates and Whole Blood Derived Platelet Concentrates
|
| Gilmore G, Thom J, Lown J, Finch S, Mapatuna K, Cobain TJ, Baker R |
| |
|
Platelet Activation Markers and Procoagulant Phenotype of Monocytes do Correlate with Markers of Reperfusion Injury Following Reperfusion after Orthotopic Liver Transplantation
|
| Schulte am Esch II J, Jurk K, Knoefel W, Röder G, Voss H, Tustas R, Hosch S, Rogiers X, Kehrel BE |
| |
|
Platelet Activation Through the GPIb-V-IX Complex: Role of Individual Subunits and the Intracellular Face
|
| Lanza F |
| |
|
Platelet Adhesion to Dimeric Beta2-Glycoprotein-I Under Conditions of Flow Is Mediated by Glycoprotein Iba
|
| Pennings MTT, Derksen RHWM, van Lummel M, Adelmeijer J, Lisman T, de Groot PG |
| |
|
Platelet ADP Receptor Function Rapidly Deteriorates in Additive Solutions
|
| Curvers J, Cauwenberghs S, Heeremans J, De Kort W, Heemskerk JWM, Keuren JFW |
| |
|
Platelet Aggregation and ATP Release Values in Children and Adults
|
| Bonduel M, Frontroth JP, Hepner M, Pieroni G, Sciuccati G, Feliú A |
| |
|
Platelet Aggregation Independent of Von Willebrand Factor and Fibrinogen
|
| Yang H, Reheman A, Chen P, Freedman J, Wagner DD, Ni H |
| |
|
Platelet Aggregation Studies: Autologous Platelet-Poor Plasma Inhibits Platelet Aggregation When Added to Platelet-Rich Plasma to Normalize Platelet Count
|
| Lecchi A, Zighetti ML, Lussana F, Cattaneo M |
| |
|
Platelet Aggregation, Microparticle Formation and Platelet-Leukocyte Conjugate Formation Induced by Combinations of 5-HT and Epinephrine Are Inhibited by Sarpogrelate and BP-984
|
| Fox SC, Manolopoulos P, May JA, Heptinstall S |
| |
|
Platelet and Inflammatory Alterations Associated with Late Restenosis in Patients Undergoing Angioplasty and Brachytherapy
|
| Jeske WP, Maszak G, Chawla R, Cho L, Lewis BE, Steen LH, Leya F, Walenga JM |
| |
|
Platelet Antibody Analysis in Patients with Platelet Transfusion Refractoriness
|
| Yan LX, Fu QH, Xu XG, He J, Zhu J |
| |
|
Platelet Associated Tissue Factor Expression in Patients with Antiphospholipid Syndrome
|
| Frigerio M, Rossi F, Veglia F, Meroni PL, Biglioli P, Tremoli E, Camera M |
| |
|
Platelet Calcium Mobilisation by Recombinant Factor VIIa Is Partially Mediated by Tissue Factor-Dependent Thrombin Generation
|
| Wilbourn B, Mackie I, Tuddenham EG, McVey JH, Machin S |
| |
|
Platelet CD40L in Chorioamnionitis
|
| Sitaru AG, Speer CP, Holzhauer S, Obergfell A, Walter U, Grossmann R |
| |
|
Platelet Changes during Cardiopulmonary Bypass in Children
|
| Ignjatovic V, Monagle P, Cochrane A, Furmedge J, Than J, Bennett M, Horton S |
| |
|
Platelet Contractile Force and Clot Elastic Modulus Measured by Hemodyne Apparatus in Intensive Care Unit Patients: Identification of Patients with High Bleeding Risk
|
| Dempfle CE, Muench E, Fiedler F, Borggrefe M |
| |
|
Platelet Derived Microparticles in Blood Bank Products Do Not Expose Functionally Active Tissue Factor But Are Highly Procoagulant
|
| Keuren JFW, Magdeleyns E, Van Oerle R, Lindhout T, Curvers J |
| |
|
Platelet Dysfunction Associated with Reduced Gai Expression in a family with Inherited Bleeding Disorder
|
| Guerrero JA, Lozano ML, Zuazu-Jausoro I, Corral J, Martinez C, Gonzalez-Conejero R, Vicente V, Rivera J |
| |
|
Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) Negatively Influences Thrombus Formation in Vivo
|
| Falati S, Gross PL, Stapleton M, Merrill-Skoloff G, Barrett NE, Pixton KL, Newman DK, Newman PJ, Furie BC, Furie B, Gibbins JM |
| |
|
Platelet Function Analyser Is a Good Alternative for Classical Bleeding Time to Detect von Willebrand Disease and Thrombocytopathy
|
| Nováková IRO, Brons P, Lubbers D, Polenewen R, Verbruggen H |
| |
|
Platelet Function Analyzer (PFA-100R) Detects Intranasal Desmopressin Responses in Patients with Hemophilia A and von Willebrand Disease
|
| Joutsi-Korhonen L, Lindqvist A-K, Lassila R |
| |
|
Platelet Function in Patients with Cerebrovascular Pathology in Changes of Geomagnetic Field of Earth
|
| Ionova V, Sazanova E, Sergeenko N, Varakin Ya |
| |
|
Platelet Function Monitoring by the PFA-100® in Patients Taking Non-Aspirin NSAIDs
|
| Ng KFJ, Lawmin JC, Tsang SF, Kwok Y, Li C, Lam CCK |
| |
|
Platelet Function of Preterm and Full Term Newborns Tested by The Cone and Plate(let) Analyzer Correlates with Gestational Age
|
| Levy-Shraga Y, Maayan-Metzger A, Lubetsky A, Shenkman B, Kuint J, Kenet G |
| |
|
Platelet Function Predicts Myocardial Damage in Patients with Acute Coronary Syndromes Treated with Multiple Antiplatelet Agents
|
| Marcucci R, Paniccia R, Giusti B, Gori AM, Mannini L, Giglioli C, Valente S, Gensini GF, Prisco D, Abbate R |
| |
|
Platelet Functions and Markers of Platelet Activation in Coronary Artery Bypass Grafting (CABG) with or without Cardiopulmonary Bypass (CPB)
|
| Zoheir Mostafa N, Gomaa M, Zayed Saleh H |
| |
|
Platelet Glycoprotein IIIa (PlA1/A2) and Plasminogen Activator Inhibitor-1 (4G/5G) Polymorphisms as Risk Factors for Coronary Artery Disease
|
| Naran NH, Chetty N |
| |
|
Platelet GPIb-IX-V-Dependent Signaling
|
| Ozaki Y, Asazuma N, Suzuki-Inoue K, Berndt M |
| |
|
Platelet Granule Secretion Mediates Platelet Aggregation and Thrombotic Arterial Occlusion
|
| King SM, Polgar J, Wang X, Reed GL |
| |
|
Platelet Hyperfunction and Low Response to Aspirin Predict Re-events in Patients With Acute Coronary Syndromes During Long Term Follow Up
|
| Fuchs I, Frossard M, Spiel A, Mayr FB, Laggner AN, Jilma B |
| |
|
Platelet Mediated Clot Formation in Whole Blood under Flow: A New Screening Method for Coagulation Disorders and for Drug Monitoring
|
| Gitel S, Brill A, Savion N, Varon D |
| |
|
Platelet Microparticles (PMP) Are Increased in Patients with Localized Prostate Cancer and Correlate with Plasma Tissue Factor (TF) Antigen Levels
|
| Langer F, Amirkhosravi A, Amaya M, Spath B, Eifrig B, Francis JL |
| |
|
Platelet Nitric Oxide Synthase (NOS) Is Negatively Regulated by Tyrosine Phosphorylation: A Novel Mechanism of eNOS Regulation
|
| Patel B, Gibbins JM, Naseem KM |
| |
|
Platelet P2Y and P2X Receptors
|
| Gachet C |
| |
|
Platelet Shape and Formation
|
| Italiano J, Patel S, Hartwig J |
| |
|
Platelet Shape Change Stimulated by Low Concentration TP Receptor Agonist Is Independent of p38 MAP Kinase Pathway Activation But Requires Myosin Activation
|
| Johnson GJ, White JG, Leis LA, Bender T |
| |
|
Platelet Thrombus Formation in Blood Vessel-Mimicking Microchannel
|
| Terada C, Uchiyama K, Tanaka S, Hori Y, Hayashi T, Hirayama F, Tani Y, Shibata H |
| |
|
Platelet–Collagen Interactions
|
|
| |
|
Platelet-Derived Factor VIII (FVIII) Is Protected from Inhibitor Inactivation – A Potential Approach for Gene Therapy of Hemophilia A with Inhibitors
|
| Shi Q, Wilcox DA, Fahs SA, Weiler H, Montgomery RR |
| |
|
Platelet-Derived Microparticles Bind Heparin with High Affinity
|
| Clutterbuck R, Dotsenko O, Kakkar VV, Scully MF |
| |
|
Platelet-Derived Microparticles Induce Angiogenesis and Stimulate Post-Ischemic Revascularization
|
| Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D |
| |
|
Platelet-Lymphocyte Conjugation: Different Behavior Between T and B Cells
|
| Ji Q, Hjemdahl P, Li N |
| |
|
Platelets Abolish the Profibrinolytic Effect of Heparin but not That of Melagatran
|
| Piro D, Rossiello MR, Rotunno C, Semeraro N, Colucci M |
| |
|
Platelets Act as Targets for Newly Identified Peripheral Tachykinins
|
| Jones S, Graham G, Hubbard GP, Gibbins JM |
| |
|
Platelets Express Steroidogenic 17b–hydroxysteroid Dehydrogenases: Distinct Profiles Predict the Essential Thrombocythemic Phenotype
|
| Gnatenko DV, Cupit LD, Huang EC, Dhundale A, Perrotta PL, Bahou WF |
| |
|
Platelets in Atherothrombosis: Lessons from Mouse Models
|
| Nieswandt B, Aktas B, Moers A, Sachs U |
| |
|
Platelets Morphological and Functional Characterisation in a Novel Case of Grey Platelet Syndrome: Defective Response to Thrombin, PAR1-AP And PAR4-AP and Correlation with Alpha-Granules Content in the Patient and Four Relatives
|
| De Candia E, Pecci A, Maggiano N, De Cristofaro R, Balduini CL, Landolfi R |
| |
|
Platelets Promote CD4+ Lymphocyte Adhesion to Extracellular Matrix and Fibronectin Under Flow: Role of Integrins, CD40 Ligand and P-Selectin Glycoprotein Ligand-1
|
| Savion N, Shenkman B, Brill G, Solpov A, Vitkovsky Y, Kuznik BI, Koltakov A, Kotev-Emeth S, Bank I |
| |
|
Platelets Provide Factor IX (FIX) and Factor X (FX) to Support Dilute Tissue-factor Dependent Coagulation
|
| Craven SJ, Dewar L, Hewett J, Pryzdial E, MacGillivray R, Ofosu FA |
| |
|
Platelets Release Matrix Metalloproteinases in the Coronary Circulation of Patients with Acute Coronary Syndromes
|
| Falcinelli E, Leone M, Cimmino G, Corazzi T, Golino P, Gresele P |
| |
|
Platelets/Endothelium Interaction and Oxidative Stress in Isolated Guinea-Pig Heart: Focus on L-Arginine/ No System and Superoxide Anion Radical Production
|
| Jakovljevic V, Mujovic VM, Novokmet SS, Djuric DM |
| |
|
Platelet-VWF Complexes Are Preferred Substrates of ADAMTS13 Under Shear Stress
|
| Shim K, Anderson PJ, Tuley EA, Sadler JE |
| |
|
Pleiotropic Functions of Thrombomodulin Domains
|
| Shi GY, Shi CS, Tseng GH, Chen PS, Wu HL |
| |
|
Podoplanin-Induced Platelet Aggregation is Responsible For Separation of Blood and Sprouting Lymphatic Vessels during Embryonic Development
|
| Uhrin P, Zaujec J, Bauer M, Breuss J, Hilpert M, Fuertbauer E, Kowalski H, Chrenek P, Stockinger H, Kerjaschki D, Binder BR |
| |
|
Polipectomia in a Patient with a Moderate Congenital Deficiency of Factor V
|
| Quintana M, Turrión P, Jimenez V, Villar A, Hernández F |
| |
|
Polymorphic Associations in Fibrinogen and Factor XIII
|
| Ariëns RAS |
| |
|
Polymorphic Markers and Arterial Thrombosis: Where Next?
|
| Carter AM |
| |
|
Polymorphism A36G of the Tumor Necrosis Factor Receptor 1 Gene Is Associated with HDL Cholesterol, TNFR1 and PAI-1 Levels in Obese Women
|
| Mavri A, Bastelica D, El Ayachi S, Peiretti S, Morange P, Verdier M, Juhan-Vague I, Alessi MC |
| |
|
Polymorphisms C807T, G873A and G1648A of Platelet Glycoprotein Ia in Young Adults with Ischemic Stroke
|
| Bykowska K, Luzak B, Windyga J, Lopaciuk S, Kwiecinski H, Czlonkowska A, Kuczynska-Zardzewialy A, Watala C |
| |
|
Polymorphisms in Genes Involved in Homocysteine Metabolism in the INCHIANTI Study
|
| Giusti B, Corsi AM, Gori AM, Lenti M, Lari B, Ferrini S, Pepe G, Ferrucci L, Gensini GF, Abbate R |
| |
|
Polymorphisms in the Hemostatic Pathway Genes and the Risk of Myocardial infarction in Patients with Advanced Coronary Artery Disease. Results from the Verona Heart Project
|
| Girelli D, Martinelli N, Olivieri O, Trabetti E, Pizzolo F, Bozzini C, Friso S, Villa G, Tenuti I, Cheng S, Lotto V, Pignatti PF, Bernardi F, Corrocher R |
| |
|
Polymorphisms Known to Increase the Risk of Atherothrombosis Do Not Affect the Risk of Thrombembolism as Determined in Patients with Atrial Fibrillation
|
| Loeffler C, Giesler U, Schwarz M, Ahrens I, Jaminet P, Bassler N, Zehender M, Bode C, Peter K |
| |
|
Polymorphonuclear Leukocytes Express Tissue Factor after Activation with P-Selectin
|
| Maugeri N, Monego G, Carbone A, de Gaetano G, Donati MB, Cerletti C |
| |
|
Polyphenolic Components of Extra Virgin Olive Oil: Effect on Arterial Thrombosis and Bioavailability in Rats
|
| De Curtis A, Giordano L, Murzilli S, Rotilio D, Donati MB, de Gaetano G, Iacoviello L |
| |
|
Population Pharmacokinetics of the ReFacto® Factor VIII for Prophylactic Treatment of HIV- and HIV+ Individuals with Haemophilia A
|
| Karafoulidou A, Anastasopoulou I, Katsarou O, Kouramba A, Kotsi P, Zografidis A, Calvo R, Lukas JC |
| |
|
Possible Interactions between Prion Protein and Transglutaminase: Irreversible Cross-Linking of Prion Protein to Fibrinogen by Factor XIIIa
|
| An SSA, Lim KT, Oh HJ |
| |
|
Possible Role for the Von Willebrand Factor Propeptide in Regulating Von Willebrand Factor Expression
|
| Messenger SL, Peake IR, Daly ME |
| |
|
Post Treatment Residual Thrombus Is Associated with an Increased Risk of DVT Recurrence, Mortality and a Trend Towards Increased Vascular Death
|
| Young L, Ockelford PA, Milne D, McKelvie S, Rolfe-Vyson V, West T, Harper P |
| |
|
Post Varicella Purpura Fulminans – Treatment with Activated Protein C Concentrate
|
| Just S, Williams B |
| |
|
Post-marketing Surveillance of Thrombotic Events Among Users of rFVIIa and FEIBA: How Costly Are These Adverse Events?
|
| Bohn RL, Aledort LM |
| |
|
Postoperative Pulmonary Embolism Detected by Multi-slice Computerized Tomography (MSCT) after Lung Surgery FcOR Cancer
|
| Milillo G, Agnelli G, Daddi G, Lupattelli L, Ragusa M, Lemmi A, Puma F, Calzolari F |
| |
|
Postprandial Hyperglycaemia Induces Platelet Activation in Type 2 Diabetes Mellitus: Effects of Treatment with Repaglinide and Glibenclamide
|
| Yngen M, Östenson C-G, Daleskog M, Johansson M-C, Li N, Hjemdahl P, Wallén NH |
| |
|
Post-splenectomy Mesenteric Vein Thrombosis: A Critical Analysis of Thrombocytosis as a Risk Factor
|
| Thatipelli MR, Wysokinski WE, Pruthi RK, McBane RD |
| |
|
Potentiation of Endothelial Nitric Oxide Synthase By Fibrinogen-bound IL-1b Requires aVb3
|
| Sahni A, Sahni SK, Francis CW |
| |
|
Pravastatin Reduces Levels of the Glycoprotein IIIa Subunit from the Fibrinogen Receptor on Platelet-Derived Microparticles in Patients with Type 2 Diabetes
|
| Sommeijer D, Joop K, Leyte A, Reitsma P, Ten Cate H |
| |
|
Preanalytical Variables and Off-Site Blood Collection: Influences on the Results of the Prothrombin Time/International Normalized Ratio Test and Implications for Monitoring of Oral Anticoagulant Therapy
|
| Van Geest-Daalderop JHH, Mulder AB, Boonman-de Winter LJM, Hoekstra MMCL, Van den Besselaar AMHP |
| |
|
Preconditioning Ischemia Favorably Attenuates Platelet Activation: Insights into Molecular Mechanisms
|
| Linden MD, Michelson AD, Frelinger III AL, Barnard MR, Furman MI, Przyklenk K |
| |
|
Precursors of Novel Gla-Containing Conotoxins Contain a Carboxy-Terminal Recognition Site that Directs g-Carboxylation by g-Glutamyl Carboxylase
|
| Brown MA, Begley GS, Czerwiec E, Stenberg LM, Jacobs M, Kalume DE, Roepstorff P, Stenflo J, Furie BC, Furie B |
| |
|
Prediction of the Excessive Perioperative Bleeding in Patients Undergoing Coronary Artery Bypass Grafting: Role of Aspirin and Platelet Glycoprotein IIIa Polymorphism
|
| Morawski W, Sanak M, Cisowski M, Szczeklik M, Szczeklik W, Dropinski J, Waclawczyk T, Szmagala P, Bochenek A, Dziedzina S, Szczeklik A |
| |
|
Prediction of the Risk of Recurrent Venous Thromboembolism by the Activated Partial Thromboplastin Time
|
| Hron G, Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Weltermann A, Kyrle PA |
| |
|
Predictive Factors for Fatal Pulmonary Embolism in 9902 Patients Presenting with an Episode of Venous Thromboembolism. Findings from the RIETE Registry
|
| Laporte S, Mismetti P, Decousus H, Uresandi F, Otero R, Lobo JL, Monreal M, the RIETE investigators |
| |
|
Predictive Factors of Failure of Lepirudine in the Treatment of Heparin-Induced Thrombocytopenia: A French-speaking Collaborative Study (GEHT)
|
| Tardy B |
| |
|
Predictive Value of ISTH DIC-Score and aPTT Waveform Analysis at Admission to the ICU
|
| Dempfle CE, Fiedler F, Muench E, Borggrefe M |
| |
|
Predictive Value of the Platelet Function Analyser (PFA-100®) for Post Biopsy Bleedings in Patients Undergoing Renal Biopsy
|
| Verbruggen HW, Polenewen RJ, Hilbrands LB, van de Kar NCAJ, Novakova IRO |
| |
|
Predictive Value of Thrombus Precursor Protein for Recurrent Venous Thromboembolism
|
| Bokarev I, Kozlova T |
| |
|
Predictors of Mid-interval Low Molecular Weight Heparin Anti-Xa Levels
|
| O'Donnell MJ, Kearon C, Johnson J, Turpie ID, Zondag M, Robinson M, Turpie AGG |
| |
|
Predictors of Recurrent Venous Thromboembolism. Balancing Benefits and Risks – A Decision Approach
|
| Prins MH, van Dongen C, Bossuyt PMM |
| |
|
Pre-Existent Variability in Platelet Response to ADP Accounts FOR ‘Clopidogrel Resistance’
|
| Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC, McLaughlin TJ, Frelinger AL |
| |
|
Pregnancy of a Libanese Woman with Homozygous Protein C deficiency
|
| Beneke H, Langer C, Struve S, Griesshammer M, Oldenburg J, Grünewald M |
| |
|
Pregnancy-associated Venous Thrombosis (VTE) in Women with Hereditary Heterozygous Factor V Leiden or Factor II 20210A Gene Mutation or Both
|
| Samama MM, Rached RA, Conard J, Horellou MH, Elalamy I |
| |
|
Pregnancy-Associated Venous Thrombosis (VTE) in Women with Hereditary Heterozygous Factor V Leiden or Factor II 20210A Gene Mutation or Both
|
| Samama MM, Rached RA, Conard J, Horellou MH, Elalamy I |
| |
|
Pregnancy-Related Arterial and Venous Thromboembolism in the United States 2000–2001
|
| James A, Jamison M, Myers E |
| |
|
Preliminary Results of a Cross-Sectional Study of Mild Hemophilia A in Newfoundland and Labrador, Canada
|
| Scully MF, MacGregor D, Walsh M, Barrett B, Kawaja M, Hann A, Harvey M, Hendry M, Sheppard C, Stuckless S, Taylor M, Xie Y-G |
| |
|
Premature Atherosclerosis in HIV Positive Patients and Cumulated Time of Exposure to Antiretroviral Therapy (SHIVA Study)
|
| de Saint Martin L, Vandhuick O, Bellein V, Guillo P, Bressollette L, Roudaut N, Amaral A, Pasquier E |
| |
|
Premature Onset of Fetal Loss Is Associated with the Polymorphism of Platelet Membrane Integrin a2b1 (a2807TT)
|
| Gerhardt A, Scharf RE, Mikat-Drozdzynski B, Krüssel JS, Bender HG, Zotz RB |
| |
|
Prenatal Diagnosis in a Lebanese Family with Severe Factor VII Deficiency
|
| Farah RA, Zalloua P, Chammas M, Schved JF, Giansily-Blaizot M |
| |
|
Preoperative Fibrin Monomer in Elective Surgery Predicts Intraoperative Blood Loss and Hospitalization Time: Results from a Confirmatory Study
|
| Korte W, Gabi K, Rohner M, Gähler A, Szadkowski C |
| |
|
Preparation of Reference Materials for the Genetic Diagnosis of Thrombophilia
|
| Gray E, Hawkins M, Byrne E, Hawkins JR, Kitchen S, Jennings I, Makris M, Preston FE, Metcalfe P |
| |
|
Presentation of Laboratory and Sonoclot Variables Using Principal Component Analysis: Identification of Hypo- and Hypercoagulation in the HELLP Syndrome
|
| Schött U, Lizka Hackzell J |
| |
|
Pretreatment with Aspirin and Loading Dose Clopidogrel Obviates the Need for Glycoprotein Iib/Iiia Antagonists During Elective Coronary Stenting
|
| Jacques Michiels J, Claeys MJ, van der Planken M, Bosmans JM, Vrints CJ |
| |
|
Prevalence and Clinical Significance of Anti-b2-Glycoprotein-I-Antibodies in Patients with Venous Thrombosis
|
| Humpich M, Schmitt J, Luxembourg B, Seifried E, Lindhoff-Last E |
| |
|
Prevalence and Clinical Significance of IgG and IgM Anti-Protein S (aPS) and Anti-Annexin V (aAV): Retrospective and Prospective Analysis of the WAPS Study
|
| Galli M, Borrelli G, Finazzi G, Marfisi RM, Marchioli R, Marziali S, Barbui T, Morboeuf O |
| |
|
Prevalence and Clinical Utility of IgA Isotype Antiphospholipid Antibodies
|
| Janatpour KA, Gosselin RC, Wun T, Owings JT, White RH, Larkin EC |
| |
|
Prevalence and Risk of Pulmonary Embolism in Patients with Intracardiac Thrombosis. A Population-Based Study
|
| Ögren M, Bergqvist D, Eriksson H, Lindblad B, Sternby NH |
| |
|
Prevalence of Acquired and Hereditary Thrombophilic Disorders in Women with Pregnancy Loss
|
| Klaeffling C, Sommerbrodt C, Luxembourg B, Lindhoff-Last E |
| |
|
Prevalence of Acquired Haemophilia A in the Malaysian Population
|
| Thiruchelvam A, Ayob Y, Staff of Haemostasis Laboratory |
| |
|
Prevalence of Deep Vein Thrombosis in Trauma: A Prospective Study of Orthopaedic Trauma Patients in Tianjin Hospital, China
|
| Lu Y, Ma B, Guo R, Wang Y, Zhang J, Wu Y, Pang G, Xin J, Ye W, Zou Y, Wang X, Hitos K, Curtin P, Fletcher J |
| |
|
Prevalence of FVL, Prothrombin G20210A and MTHFR C667T in Saudi Arabia: A preliminary report for the Saudi Thrombosis and Familial Thrombophelia (S-TAFT) Registry
|
| Saour J, Mammo L |
| |
|
Prevalence of Genetic Risk Factors Causing Thrombophilia in Normal Population and Recurrent Abortions Patients in Saudi Arabia
|
| Abuzenadah AM, Chaudhary AGA, Gari MA, Qahtani MH |
| |
|
Prevalence of Helicobater Pylori Infection and Clinical Response to Eradication Therapy in Patients Wwith Immune Thrombocytopenic Purpura (ITP)
|
| Scandellari R, Allemand E, Pacquola E, Randi ML, Luzzatto G, Fabris F |
| |
|
Prevalence of Inflammatory Gene Polymorphisms in Nonvalvular Atrial Fibrillation Patients
|
| Gori AM, Gensini F, Cecchi E, Brogi D, Michelucci A, Padeletti L, Porciani MC, Prisco D, Abbate R, Gensini GF |
| |
|
Prevalence of Inherited Thrombophilia in Severe OHSS
|
| Machac S, Lubusky M, Prochazka M, Slavik L |
| |
|
Prevalence of Risk Factors for Venous Thromboembolism: A Study from North India
|
| Garewal G, Das R, Ahluwalia J, Mittal N, Varma S |
| |
|
Prevalence of the Metabolic Syndrome in Patients with Provoked or Unprovoked Deep Vein Thrombosis and in Controls
|
| Ageno W, Romualdi E, Ghirarduzzi A, Dentali F, Pesavento R, Prandoni P, Steidl L, Venco A |
| |
|
Prevalence of Thrombophilic Abnormalities in Patients with Deep Vein Thrombosis or Pulmonary Embolism
|
| Becattini C, Agnelli G, Prandoni P, Taliani MR, Ageno W, Silingardi M, Moia M, Bazzan M, Miccio M, Guazzaloca G, Imberti D, Poggio R, Pogliani E, Bertoldi A, Ria L |
| |
|
Prevalence of Thrombophilic Mutations and Polymorphisms in Cases of Recurrent Pregnancy Loss (RPL)
|
| Ghosh K, Vora S, Shetty S, Mohanty D |
| |
|
Prevalence of type 2N von Willebrand Disease in Indian VWD patients
|
| Trasi S, Ghosh K, Shrimati S, Shetty S, Mohanty D |
| |
|
Preventable Stroke and Stroke Prevention
|
| Hankey GJ |
| |
|
Prevention of Anti-FVIII-C2 inhibitor formation Post Protein infusion in Hemophilic Mice By Prior Oral and/or Nasal Exposure of the FVIII-C2 Domain
|
| Rawle F, Labelle A, Davie E, Pratt K, Hough C, Lillicrap D |
| |
|
Prevention of Canine Coronary Artery Thrombosis by the von Willebrand Factor Antagonist, GPG290
|
| Shaw GD, Hennan JK, Swillo RE, Morgan G, Brooks JM, Sako D, Schaub RG, Crandall DL |
| |
|
Prevention of Postoperative Pulmonary Embolism in the Japanese Academic Medical Center
|
| Yasuda C, Taniguchi M, Fukuda K, Okada K, Ueshima S, Matsuo O, Hirohata K, Yuasa H, Shiokawa Y, Koga Y, Ohyanagi H, Shiozaki H |
| |
|
Prevention of Recurrent Venous Thromboembolism – with What Agents and for How Long?
|
| Schulman S |
| |
|
Prevention of Venous Thromboembolism with an Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – in Elective Hip Replacement: A Dose-Ranging Study
|
| Eriksson BI, Borris LC, Dahl OE, Haas SK, Huisman MV, Kakkar AK, Kälebo P, Misselwitz F, Mühlhofer EM |
| |
|
Prevention of Venous Thromboembolism with Low-Molecular-Weight Heparin in Patients with Metastatic Breast or Lung Cancer – Results of the TOPIC Studies
|
| Haas SK, Kakkar AK, Kemkes-Matthes B, Freund M, Gatzemeier U, Heilmann L, von Tempelhoff GF, Brom J, Weidinger G |
| |
|
Principal Component Analysis to Evaluate Aprotinin Treatment in Abruptio Placentae Patients with Severe Bleeding
|
| Schött U, Lizka Hackzell J |
| |
|
Probable Involvement of Endogenous Platelet Protease(s) in PAR-Dependent Platelet Activation
|
| Cedrone A, Yang X, Craven SJ, Ofosu FA |
| |
|
ProC Global Assay in the Evaluation of Women at Risk for VTE While Using Hormonal Therapy
|
| Sarig G, Aberbach I, Schliamser L, Blumenfeld Z, Zlotzover M, Brenner B |
| |
|
Procoagulant Phospholipid Activity Associates Not Only with Free Microparticles, But with Platelets and/or Microparticles Complexed to Erythrocytes and Leukocytes
|
| Connor DE, Exner T, Ma DDF, Joseph JE |
| |
|
Production and Characterization of a Novel, Recombinantly-modified Plasmin Molecule
|
| Hunt J, Novokhatny V |
| |
|
Production of a Recombinant Peptide Substrate for the Fluorescence Based Assay of ADAMTS13
|
| Zhang L, Lawson HL, Huff JD, Harish VC, Owen J |
| |
|
Production of Anti-ADAMTS-13 Monoclonal Antibodies by DNA Immunization
|
| Feys HB, De Bruin K, Pareyn I, Vauterin S, Noppe W, Deckmyn H, Vanhoorelbeke K |
| |
|
Pro-Fibrinolytic Monoclonal Antibodies That Convert a2-Antiplasmin from a Plasmin Inhibitor to a Substrate
|
| Sazonova I, Thomas B, Gladysheva I, Houng A, Reed G |
| |
|
Prognostic Role of Inflammatory Markers in Elderly Patients with Acute Ischemic Stroke
|
| Masotti L, Ceccarelli E, Cappelli R |
| |
|
Prognostic Value of Echocardiography and Chest Computed Tomography in Patients with Pulmonary Embolism
|
| Gibson NS, Söhne M, Gerdes VEA, Büller HR |
| |
|
Proinflammatory Cytokines Impair Endothelial Fibrinolytic Capacity Partly Independently of NFkB
|
| Ulfhammer E, Karlsson L, Ridderstråle W, Hrafnkelsdottir T, Jern S |
| |
|
Project HemIS (Haemophilia – Information System): Multicentric Information System of Patients with Haemophilia
|
| Penka M, Mu[zcaron]ík J, Du[scaron]ek L, Blatný J, Smejkal P, Komrska V, Salaj P, Klime[scaron] D, [Scaron]nábl I, Matý[scaron]kova M, Pták J, Hrachovinová I, Ptoszková H, Bla[zcaron]ek B, Buliková A, Kr[ccaron]ová V |
| |
|
Prolonged Anticoagulation and Sustained Therapeutic Endogenous Activated Protein C (APC) Levels during Protein C Activation in Primates by a Thrombin Variant
|
| Gruber A, Fernández JA, Bush L, Marzec U, Griffin JH, Hanson SR, Di Cera E |
| |
|
Prolonged Euglobulin Clot Lysis Time does not Always Indicate Impaired Fibrinolysis in Chronic Hemodialysis Patients
|
| Rydzewska-Rosolowska A, Borawski J, Naumnik, Mysliwiec M |
| |
|
Prolonged Extracorporeal Life Support (ECLS) in Patients with Severe Membrane Stabilizing Agent (MSA) Poisonings: Hemostatic Management Requires only Minimal Doses of Heparin
|
| Semmache Y, Guerrier G, Bellucci S, Hadj-Ali A, Boval B, Megarbane B, Baud F, Drouet L |
| |
|
Prolonged Thromboprophylaxis with Dalteparin May Improve Survival in Patients Operated on for Abdominal Cancer
|
| Rasmussen MS, Jorgensen LN, Wille-Jørgensen P, Nielsen JD, Horn A, Mohn AC, Sømod L, Olsen B, Pilsgaard B, Harvald T |
| |
|
Prolylcarboxypeptidase (PRCP): Characterization of Truncated Forms
|
| Shariat-Madar Z, Rife DC, Mahdi F, Schmaier AH |
| |
|
Prolylcarboxypeptidase Activates Plasma Prekallikrein on Transfected CHO Cells
|
| Shariat-Madar Z, Rahimy E, Mahdi F, Schmaier AH |
| |
|
Prophylaxis for Hemophilia A and B – Present and Future
|
| Kalev I, Kabakchieva R, Petrova G, Shopova S |
| |
|
Prophylaxis in Non-surgical Patients
|
|
| |
|
Prophylaxis in Non-Surgical Patients
|
| Gallus A |
| |
|
Prophylaxis of Thromboembolic Complications in Acute Ischemic Stroke with the Low Molecular Weight Heparin Certoparin (PROTECT)
|
| Harenberg J, Diener HC, Ringelstein EB, von Kummer R, Landgraf H, Koppenhagen K, Brom J, Weidinger G |
| |
|
Prophylaxis using a Novel Oral Small Molecule Inhibitor to the P-selectin Receptor Promotes Thrombus Resolution in a Baboon Model of Venous Thrombosis
|
| Myers D, Wrobleski S, Longo C, Bedard P, Kaila N, Shaw G, Londy F, Fex B, Farris D, Henke P, Schaub R, Wakefield T |
| |
|
Prophylaxis with Factor Eight Inhibitor Bypassing Activity, Vapor Heated (FEIBA VH) Decreases Bleeding Frequency and Maintains or Improves Joint Status
|
| Leissinger CA, Becton DL, Ewing NP, Valentino LA |
| |
|
Prophylaxis with Factor VIII Protects Children with Hemophilia a from Inhibitor Development
|
| Santagostino E, Mancuso ME, Rocino A, Mazzucconi MG, Mancuso G, Tagliaferri A, Messina M, Luciani M, Boeri E, Mannucci PM |
| |
|
Proportion of Major Bleeds That Are Intracranial or Fatal According to Indication for Oral Anticoagulant Therapy
|
| Linkins LA, Julian J, Kearon C |
| |
|
Proposal of Immunotolerance Induction in Haemophiliacs A with Inhibitors Undergoing to Pressing Elective Surgery by Using FVIII/vWF-enriched Pure Plasmaderivates
|
| R Musso, D Cultrera, S Motta, C La Greca, M Musso, A Cipolla, R Giustolisi |
| |
|
Pros and Cons of Rituximab Administration Use in Patient with Immune Thrombocytopenia and Antiphospholipid Antibodies
|
| Kopec I, Windyga J, Misiak A, Wislawski S, Szczepanik AB, Warzocha K |
| |
|
Prospective Evaluation of Low PAI-1 Activity as a Risk Factor for Hemorrhagic Diathesis
|
| Schulman S, Ågren A, Holmström M, Stiller V, Lindmarker P, Sten-Linder M, Wiman B |
| |
|
Prospective Investigations of the Predictive Value of hs-CRP in Patients with and without the Presence of Antiphospholipid Antibodies
|
| Miesbach W, Claus D, Scharrer I |
| |
|
Prospective Sensitivity Comparison of Three Different D-Dimer Assays for Venous Thromboembolic Disease Exclusion Using a Standardized Diagnostic Algorithm
|
| Blais N, Chénier M, L'Abbé D, Lachance P-A, Notebeart E, Ouellet J, Paradis B |
| |
|
Prospective Study of the Diagnosis of Pulmonary Embolism (PE) Using Pretest Probability (PTP), D-Dimer (DD) and Appropriate Imaging
|
| Patel RK, Bagot C, Lambie J, Desai S, Arya R |
| |
|
Prospective Study on Acute Thrombotic Microangiopathy (TMA) after Bone Marrow Transplantation (BMT): Role of ADAMTS13, VWF:Ag and High Molecular Weight von Willebrand Factor (HMW : VWF)
|
| Peyvandi F, Siboni SM, Lavoretano S, Canciani MT, Coppola R, Lambertenghi D, Lambertenghi Deliliers G, Mannucci PM |
| |
|
Protamine Sulfate Is Capable of Neutralizing Bacterial Core Polysaccharide Derived Sulfaminoheparosans
|
| Cornelli U, Maddineni J, Manoni M, Hoppensteadt D, Fareed J |
| |
|
Protamine Sulphate Neutralization of Anti-Xa and APTT Activities of Low Molecular Weight Heparin Oligosaccharides
|
| Hogwood J, Gray E, Mulloy B |
| |
|
Protease-Activated Receptors in Hemostasis, Thrombosis and Vascular Biology
|
|
| |
|
Protective Effect of Endothelial Injury Administrated by Antithrombin Concentrates and Neutrophil Elastase Inhibitor in Endotoxin-Treated Rat
|
| Eguchi Y, Terada Y, Hasegawa H, Tani T |
| |
|
Protective Effect of Human Plasma-Derived Protein C in Septic Neonatal Mice
|
| Muchitsch E-M, Schwarz HP, Váradi K, Esmon C, Mancuso G, Teti G |
| |
|
Protective Effects of GYKI-66476 and GYKI-66430 in Experimental Models of Disseminated Intravascular Coagulation (DIC)
|
| Szabó G, Barabás É, Bajusz S |
| |
|
Protective Role of the Platelet GP IIIa Polymorphism HPA-1 (PlA) in Subarachnoid Hemorrhage
|
| González-Conejero R, Iniesta JA, Piqueras C, del Rey ML, Vicente V, Corral J |
| |
|
Protein C Inhibitor Plays a Role as a Potent Regulator of Activated Hepatocyte Growth Factor Activator
|
| Suzuki K, Nishioka J, Hayashi T, Naka D, Nagaike K, Kobayashi T, Hattori A |
| |
|
Protein C/S Ratio Improves Accuracy to Identify Hereditary Protein S Deficiency Type I. Results from a Family Cohort Study (DESCARTES)
|
| Ten Kate MK, Brouwer JLP, Veeger NJGM, Van der Meer J |
| |
|
Protein C/S Ratio to Identify Protein S Type I Non-Deficient Relatives at High Risk of Venous Thromboembolism (VTE). Results from a Family Cohort Study (DESCARTES)
|
| Ten Kate MK, Brouwer JLP, Veeger NJGM, Van der Meer J |
| |
|
Protein CValencia: Symptomatic Type II Protein C Deficiency Associated with a Mutation in the Gla Domain (Glu16 to Lys)
|
| Navarro S, Medina P, Estellés A, Mira Y, Villa P, Ferrando F, Vayá A, Bertina RM, Aznar J, España F |
| |
|
Protein Chip Array Profiles in End Stage Renal Disease (ESRD) Patients
|
| Bansal V, McCriskin B, Tobu M, Iqbal O, Hoppensteadt D, Fareed J |
| |
|
Protein Kinase A-dependent Clustering of Weibel-Palade Bodies in Endothelial Cells
|
| Rondaij MG, Bierings R, Gijzen KA, van Mourik JA, Fernandez-Borja M, Voorberg J |
| |
|
Protein Profiling of Human Blood Platelets from Young and Aged Individuals
|
| Zellner M, Winkler W, Rappold E, Garo F, Miller I, Chang M, Grillari J, Staes A, Hugelier K, Vandekerckhove J, Gevaert K, Oehler R |
| |
|
Protein S Multimers and Monomers Each have Direct Anticoagulant Activity and Exist in Plasma
|
| Heeb MJ |
| |
|
Protein S Multimers are Generated in vitro and do Not Bind to C4b-binding Protein: Implications for Protein S Structure-Function Analysis
|
| Kristin MS, George MW, Guido T, Jan R, Tilman MH |
| |
|
Protein S Suppresses Invasive Potential of THP-1 Cells by Lowering Binding Capacity of Plasminogen on Cell Surface
|
| Hryszko T, Suzuki Y, Ihara H, Mogami H, Urano T |
| |
|
Protein Tyrosine Kinase, Syk, Involved in Immune Platelet Phagocytosis, Also Plays a Role in Human Macrophage Cell-Cell Interactions and PECAM-1 Mediated Signal Transduction
|
| Beardsley DS, Chen BG, Kruglov O |
| |
|
Protein Z and the Protein C System in Normal Pregnancies and Patients with Early Foetal Loss
|
| Van Dreden P, Rousseau A, Fontaine S, Favier R, Woodhams B |
| |
|
Protein Z Decreases During Follow-up of Patients with Acute Coronary Syndromes
|
| Sofi F, Cesari F, Fedi S, Fatini C, Tellini I, Valente S, Vigiani S, Beconcini S, Abbate R, Gensini GF |
| |
|
Protein Z Gene Polymorphisms, Protein Z Concentration and Ischaemic Stroke
|
| Staton JM, Sayer MS, Cole VJ, Hankey GJ, Thom J, Yi Q, Baker RI, Eikelboom JW |
| |
|
Protein Z Plasma Levels in Different Phases of Activity of Coronary Atherosclerosis
|
| Fedi S, Sofi F, Cesari F, Vigiani S, Fatini C, Marcucci R, Giglioli C, Margheri M, Abbate R, Gensini GF |
| |
|
Protein Z Polymorphisms and Cerebral Venous Thrombosis
|
| Le Cam-Duchez V, Bagan-Triquenot A, Chrétien MH, Duclos M, Mihout B, Borg JY |
| |
|
Protein Z Polymorphisms, Protein Z Plasma Concentration and Severe Pre Eclampsia
|
| Le Cam-Duchez V, Verspyck E, Chrétien MH, Duclos M, Marpeau L, Borg JY |
| |
|
Proteinase 3 Expression on Neutrophil Membranes from Patients with Infectious Disease
|
| Matsumoto T, Kaneko T, Wada H, Kobayashi T, Abe Y, Nobori T, Shiku H, Stearns-Kurosawa DJ, Kurosawa S |
| |
|
Protein-Biochemical Characterisation of Wilate®: Determination of the Upper Residual Moisture Limit during Terminal Dry-Heat Treatment
|
| Kannicht C, Stadler M, Neisser-Svae A, Gruber G |
| |
|
Proteolysis of CCN1 (Cyr61) by Plasmin: Functional Implications
|
| Pendurthi U, Tran T, Rao LVM |
| |
|
Proteolysis of Streptokinase during Plasminogen Activation Regulates the Potency and Specificity of Fibrinolysis
|
| Sazonova I, Houng A, Reed G |
| |
|
Proteomic Analysis of High-Density Lipoprotein
|
| Rezaee F, Levels JHM, Casetta B, Speijer D, Meijers JCM |
| |
|
Proteomic Analysis of Platelets and Platelet-Derived Microparticles by iTRAQ Labeling and Mass Spectrometry
|
| Perez-Pujol S, Martinez MB, Higgins LA, Nelsestuen GL, Key NS |
| |
|
Proteomic Analysis of The Low Molecular Weight Platelet Secretome Reveals the Presence of Novel N-Terminal Thrombospondin-1 Fragments
|
| Culligan K, Moran N, Kiernan A, Treumann A |
| |
|
Proteomic Profiles in Critically Ill Emergency Department Patients, Utilizing ProteinChip Array Technology
|
| Fareed J, McCriskin B, Maddineni J, Florian M, Cichon M, Walenga J, Hoppensteadt D, Chyna B, Wahi R, Jeske W |
| |
|
Proteomics as a Tool for Assessment of Therapeutics in Transfusion Medicine: Evaluation of Prothrombin Complex Concentrates
|
| Brigulla M, Thiele T, Scharf C, Breitner-Ruddock S, Venz S, Völker U, Greinacher A |
| |
|
Prothrombin Activators from Snake Venoms Similar to Mammalian Blood Coagulation Factors
|
| Kini RM |
| |
|
Prothrombin Binding to Phospholipid Membranes – A Proposed Mechanism
|
| Smith E, Vekaria R, Brown K, Clongstaff C |
| |
|
Prothrombin Colocalizes to the Platelet Thrombus and Vessel Wall Interface after Laser Induced Thrombosis Injury
|
| Baird TR, Panizzi PR, Chang N, Bock PE, Furie B, Furie BC |
| |
|
Prothrombin Complex Methods Are Most Sensitive for Prothrombin, Less for Factor VII and Much Less for Factor X, But the Contribution of the Different Factors, Vitamin K Dependent and Non-dependent Factors, Varies a Lot between Reagents
|
| Gustafsson KM, Arbring K, Lindahl TL |
| |
|
Prothrombin Fragment 1 and Annexin V Localize Differently after Laser Induced Vascular Injury in vivo
|
| Pauer HU, Baird TR, Johnston K, Seaton BA, Furie B, Furie BC |
| |
|
Prothrombin G20210A and Factor V Leiden Mutations in Southern Iran
|
| Karimi M, Afrasiabi AR, Panahandeh G, Peyvandi F |
| |
|
Prothrombin Time (PT) Determination in Plasma by Wet Chemistry Analysis of Blood with Concomitant Hematocrit Determination, Simple Simon PT
|
| Ranby M, Danielsson M |
| |
|
Prothrombin Time Determination at Ambient Room Temperature
|
| Danielsson M, Ranby M |
| |
|
Prothrombotic Potential of Sclerosants: In Vitro Effects on Coagulation, Red cells and Platelets
|
| Parsi K, Exner T, Ma DDF, Joseph JE |
| |
|
Prothrombotic Risk Assessment of Patients Receiving Ximelagatran for Secondary Prevention of Venous Thromboembolism
|
| Wåhlander K, Eriksson H, Lundström T, Billing Clason S, Wall U, Nyström P, Wessman P, Schulman S |
| |
|
Prothrombotic Risk Factors of Fabry Patients in Argentina
|
| Martinez P, Aggio M |
| |
|
Prothrombotic Tendency upon Inflammatory Conditions – Alpha Defensins (HNP-1/2/3) Are Strong Platelet Agonists
|
| Brodde MF, Horn M, Van Aken H, Niemann S, Jurk K, Kehrel BE |
| |
|
Prourokinase Activation Is the Speed-limited Step of Its Catalyzed Plasminogen Activation
|
| Zhang J, Chen Y, Liu J |
| |
|
P-selectin- and CD63-Exposing Platelet Microparticles Reflect Platelet Activation in Peripheral Arterial Disease and Myocardial Infarction
|
| van der Zee PM, Biró E´, Ko Y, de Winter RJ, Hack CE, Sturk A, Nieuwland R |
| |
|
P-selectin Antagonist Gallic Acid is Antithrombotic Via Inhibition of Circulating Tissue Factor Deposition in Developing Murine Arterial Thrombi
|
| Daenens K, Melis E, Van kerckhoven S, Hoylaerts MF |
| |
|
Pseudo von Willebrand Disease: 2B or not 2B? Cryoprecipitate Induced Platelet Aggregation Solves Hamlet's Dilemma
|
| Enayat MS, Guilliatt AM, LesterO'Connor WNTJ, Williams MD, Hill FGH |
| |
|
Pulmonary Thromboembolism in Cancer Patients Autopsied in a Japanese General Hospital
|
| Sakon M, Nishikawa Y, Itani Y, Nakagawa S, Amano M, Hayashida H, Higaki N, Niinobu T, Ayata M, Ikeda M |
| |
|
Purification and Characterization of Recombinant Antithrombin Expressed in Chinese Hamster Ovary Cells
|
| Hirose M, Mochizuki S, Miyano K, Kondo M, Masaki A, Hamato N, Tsukada M, Ohi H |
| |
|
Putative Prothrombotic Polymorphisms in Patients with Antiphospholipid Antibodies
|
| Stuart-Smith SE, Hunt BJ, McVey JH |
| |
